Why Is PHATHOM PHARMACEUTIC (PHAT) Stock Moving Today?

Phathom Pharmaceuticals stock is moving today as a result of a recent downgrade from Barclays. The bank reduced its price target for the stock from $18 to $14, signaling a shift in analyst expectations. This comes amid a broader trend of mixed analyst coverage and recent adjustments to the company's financial guidance.

What Happened

Barclays lowered its price target for Phathom Pharmaceuticals to $14 from $18, reflecting a more cautious outlook on the stock. This move follows recent updates from the company, including a downward revision of its full-year 2026 sales guidance. Phathom now expects revenue in the range of $310 million to $325 million, down from its previous forecast of $320 million to $345 million. The company reported Q2 adjusted earnings per share of $0.00, which beat the estimated loss of $0.25, and revenue of $74.3 million, exceeding the estimated $72.789 million. Despite these positive quarterly results, the updated guidance has led to a more tempered analyst outlook.

What The Data Shows

Phathom Pharmaceuticals has a market capitalization of $666.4 million and remains unprofitable, with an earnings per share of -1.27 over the trailing twelve months. The company has reported a 110.2% year-over-year revenue increase, but its net margin remains negative at -41.3%. The stock has traded between $8.21 and $18.31 over the past 52 weeks and has a beta of 0.50, indicating lower volatility compared to the broader market. Analyst sentiment has deteriorated over the past week, with a score of 34 out of 100 compared to a 30-day average of 48.

What To Watch

Phathom Pharmaceuticals has not scheduled an earnings report in the near term. Investors should monitor the breadth of analyst coverage and any further revisions to the company's financial guidance.